Modeling the response of pneumonia to antimicrobial therapy

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1269-1274

  Hyatt, Judith M ^a   Luzier, Aileen Bown ^a   Forrest, Alan ^a   Ballow, Charles H ^a   Schentag, Jerome J ^a  

^a Millard Fillmore Gates Circle Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFMENOXIME; CEFTAZIDIME; CIPROFLOXACIN;

ADULT; ANALYTIC METHOD; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; IMMUNE RESPONSE; MODEL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0030907628     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1269     Document Type: Article

References (21)

1. Bittner, M. J., M. P. Pugsley, E. A. Horowitz, D. G. Strike, C. C. Sanders, and L. C. Preheim. 1986. Randomized comparison of ceftriaxone and cefamandole therapy in lower respiratory tract infections in an elderly population. J. Antimicrob. Chemother. 18:621-627.
2. Durocher, A., F. Saulnier, R. Beuscart, F. Dievart, F. Bart, R. Deturck, and F. Wattel. 1988. A comparison of three severity score indexes in an evaluation of serious bacterial pneumonia. Intensive Care Med. 14:39-43.
3. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Schentag, G. A. Siamai, R. L. Zameck, D. C. Haverstock, H. H. Reinhart, R. M. Echols, and the Severe Pneumonia Study Group. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
4. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
5. Gerber, A. U., A. P. Vastola, J. Brandel, and W. A. Craig. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J. Infect. Dis. 146:691-697.
6. Goss, T. F., A. Forrest, D. E. Nix, C. H. Ballow, M. C. Birmingham, T. J. Cumbo, and J. J. Schentag. 1994. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann. Pharmacother. 28:863-867.
7. Hyatt, J. M., D. E. Nix, C. W. Stratton, and J. J. Schentag. 1995. Relative potential for five classes of antimicrobial agents, alone and in combination, to select/induce oxacillin resistance (OR) in susceptible Staphylococcus aureus (SA), abstr. C129, p. 63. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Knaus, W. A., J. E. Zimmerman, D. P. Wagner, E. A. Draper, and D. E. Lawrence. 1983. Apache:acute physiology and chronic health evaluation; a physiologically based classification system. Crit. Care Med. 9:591.
9. Le Gall, J. R., P. H. Loirat, and A. Alperovitch. 1983. Simplified acute physiological score for intensive care patients. Lancet ii:741.
10. Lerner, S. A., C. A. Lavieri, and E. M. Quimosing. 1988. Selection of ciprofloxacin-resistant mutants in vitro from clinical isolates of Pseudomonas aeruginosa and other bacteria in an in vitro two-compartment capillary model. Rev. Infect. Dis. 10(Suppl. 1):34-35.
11. Lode, H., R. Wiley, G. Hoffken, J. Wagner, and K. Borner. 1987. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob. Agents Chemother. 31:1491-1496.
12. Luzier, A., T. F. Goss, T. Cumbo, and J. J. Schentag. 1992. Mathematical examination of dual individualization principles (III): development of a scoring system for LRTI staging and quantitation of responses to antibiotics: results in cefmenoxime treated patients. DICP - Ann. Pharmacother. 26: 1358-1365.
13. Mandell, L. A., L. E. Nicolle, A. R. Ronald, R. Duperval, H. G. Robson, R. Feld, J. Vincelette, and I. Fong. 1983. A multicenter prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. J. Antimicrob. Chemother. 12(Suppl.A):9-20.
14. Meads, M., H. W. Harris, and M. Finland. 1945. Treatment of pneumococcal pneumonia with penicillin. N. Engl. J. Med. 232:749-755.
15. Peloquin, C. A., T. J. Cumbo, D. E. Nix, M. F. Sands, and J. J. Schentag. 1989. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Arch. Intern. Med. 149:2269-2273.
16. Rapp, R. P., M. Billeter, J. Hatton, A. B. Young, P. A. Tibbs, and R. J. Dempsey. 1991. Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clin. Pharm. 10:49-55.
17. Schentag, J. J., I. L. Smith, D. J. Swanson, C. DeAngelis, J. E. Fracasso, A. Vari, and J. W. Vance. 1984. Role for dual individualization with cefmenoxime. Am. J. Med. 77(Suppl. 6A):43-50.
18. Schentag, J. J., A. J. Vari, N. E. Winslade, D. J. Swanson, I. L. Smith, G. W. Simons, and A. Vigano. 1985. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am. J. Med. 78(Suppl. 2A):34-41.
19. Steinberg, D., and P. Colla. 1991. LOGIT: A supplementary module for SYSTAT. SYSTAT Inc., Evanston, Ill.
20. Trenholme, G. M., J. C. Pottage, and P. H. Karakusis. 1985. Use of ceftazidime in the treatment of nosocomial lower respiratory infections. Am. J. Med. 79(Suppl. 2A):32-36.
21. Tumulty, P. A., and G. Zubrod. 1948. Pneumococcal pneumonia treated with aqueous penicillin at twelve-hour intervals. N. Engl. J. Med. 239:1033-1036.